Austin Biosciences, LLC (ABS) is pioneering a cancer diagnostic test that has never been offered in the healthcare market and is highly sensitive in the early detection of malignant cancer.

 

ABS has obtained exclusive global rights for this novel cancer diagnostic test after licensing this technology from the University of Minnesota.  The goal of ABS is to further develop and commercialize this first-ever metabolomics-based blood test for early cancer screening or detection.